Anti-PML (Human) mAb

Acute promyelocytic leukemia (APL) is associated with a t(15;17) translocation that creates the promyelocyte-retinoic acid receptor ? (PML-RAR?) fusion protein and successfully differentiated by all-trans-retinoic acid (ATRA). PML-RAR? consists of all amino acid of RAR? except the first 59 amino acids and includes its DNA-binding and ligand-binding domains. PML-RAR? contains the functional domains of PML which includes the DNA binding and dimerization property. Thus, the functions of PML and/or retinoid X receptor are sequestrated by PML-RAR? in a dominant negative manner. In APL cells, the PML-RAR? and PML are immunologically localized as microgranules in the nuclei and cytoplasm, whereas in normal cells, PML is immunologically found as a discrete speckled pattern in nuclei. The ATRA treatment of the APL cells triggers a reorganization of PML to generate normal localization. Anti-PML antibody is a strong tool for the detection of the chromosomal translocation t(15;17) on the APL cells and/or determination of the sensitivity of the APL cells to the ATRA differentiation of hematopoietic cells and apoptosis.